Holen Sie sich die Stockscreener-App
3.90
2.50%
-0.10
Handel nachbörslich:
3.80
-0.10
-2.56%
Schlusskurs vom Vortag:
$4.00
Offen:
$3.92
24-Stunden-Volumen:
240.77K
Relative Volume:
0.70
Marktkapitalisierung:
$233.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.33M
KGV:
-0.6533
EPS:
-5.97
Netto-Cashflow:
$-39.53M
1W Leistung:
-21.37%
1M Leistung:
+31.31%
6M Leistung:
+29.14%
1J Leistung:
+207.09%
1-Tages-Spanne:
$3.76
$4.07
1-Wochen-Bereich:
$3.76
$5.00
52-Wochen-Spanne:
$1.1099
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Vergleichen Sie ELDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ELDN | 3.90 | 233.58M | 0 | -40.33M | -39.53M | -5.97 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Research Analysts Set Expectations for ELDN FY2024 Earnings - MarketBeat
FY2024 Earnings Forecast for ELDN Issued By Lifesci Capital - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance
Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St
Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter
Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian
Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia
Eledon Pharmaceuticals initiates $75 million stock sale agreement - Investing.com
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewswire
ELDNEledon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Eledon Announces Completion of Enrollment in Phase 2 BESTOW - GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - StockTitan
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 6.8% - MarketBeat
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):